KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | MicrobiomeTrials
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-12-19Est. Completion: 2033-01-14
Enrollment target: 130 participants
Locations
Clermont Oncology Center ( Site 0041), Clermont, Florida, United States
Sanford Health Roger Maris Cancer Center ( Site 0039), Fargo, North Dakota, United States
Sanford Cancer Center Oncology Clinic ( Site 0038), Sioux Falls, South Dakota, United States
Centro de Oncología de Precisión ( Site 0160), Santiago, Region M. de Santiago, Chile
West China Hospital, Sichuan University ( Site 0315), Chengdu, Sichuan, China
Kuopion Yliopistollinen Sairaala ( Site 0261), Kuopio, Northern Savonia, Finland
Vaasan Keskussairaala ( Site 0263), Vaasa, Pohjanmaa, Finland
Turku University Hospital ( Site 0262), Turku, Southwest Finland, Finland
HYKS Syöpätautien klinikka ( Site 0260), Helsinki, Uusimaa, Finland
Hong Kong United Oncology Centre ( Site 0231), Kowloon, Hong Kong
Queen Mary Hospital ( Site 0230), Pokfulam, Hong Kong
Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175), Milan, Lombardy, Italy
Deventer Ziekenhuis ( Site 0272), Deventer, Overijssel, Netherlands
Leids Universitair Medisch Centrum ( Site 0273), Leiden, South Holland, Netherlands
Other microbiome trials you might be interested in